Navigation Links
Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
Date:9/25/2008

NEW YORK, Sept. 25 /PRNewswire/ -- Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) announced that notification was received today that its patent application entitled, "Low Oxygen Organic Waste Bioconversion System" has been granted by the Commonwealth of Australia Patent Office and given a Standard Patent number of 2002227224. The official filing date is approved as November 8, 2001 and the patent will be in force until an expiration date of November 8, 2021.

This patent now fully protects the core Bion process as applied in all Bion Environmental Management System configurations in this important livestock and dairy production country. Bion's international intellectual property protection currently includes issued patents in the key markets of Canada, Mexico, New Zealand and now Australia. In addition Bion has patents pending in the entire European Union, Brazil, and Argentina.

About Bion: Bion has provided solutions to the agriculture and livestock industry since 1990, with 30 first-generation systems installed through 2003. Bion's next-generation technology results from 18 years of research & development, testing, commercial deployment, and further adaptation to evolving standards and opportunities. In addition to providing proven comprehensive environmental treatment, the system recovers cellulosic biomass from the waste stream to produce renewable energy in a process different and much more efficient than others that seek to exploit this energy source. The technology is scalable, proven and quickly gaining acceptance by regulatory agencies and other stakeholders as an effective solution to the environmental issues associated with concentrated livestock waste. For more information, see Bion's website: http://www.biontech.com.

This material includes forward-looking statements based on management's current reasonable business expectations. In this document, the word '
'/>"/>

SOURCE Bion Environmental Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
... Jan. 7 Sangart, Inc., a privately ... and,commercialization of oxygen-therapeutic agents, today announced a ... key leadership positions and,a significant reduction in ... This restructuring reduces the company,s burn rate ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
Cached Biology Technology:Volcano Announces Closing of Axsun Technologies Acquisition 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... mountains are thinning is not disputed. However, few researchers ... Lawrence Berkeley National Laboratory scientist Surabi Menon set out ... culpritgreenhouse gases, such as carbon dioxidefrom other particles in ... and her collaborators found that airborne black carbon aerosols, ...
... 3, 2010 For Immediate Release A team of ... that act on novel binding sites for an enzyme used ... AIDS. The discovery lays the foundation for the development of ... treat drug-resistant strains of the disease, and slow the evolution ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
... Ultrapure ACS Reagent Grade C 19 H ... Weight: 691.95 PRODUCT SPECIFICATIONS Form: Powder Clarity ... pH 3.0 - Yellow pH ... tracking dye in agarose and acrylamide gel ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... CHEMICONs ELF 97 Cytological Labeling Kit ... facilitate the detection of cellular targets, including ... 97 Cytological Labeling Kit contains the patented ... brightly fluorescent yellow-green precipitate at the site ...
Biology Products: